Last reviewed · How we verify
GI265235
GI265235 is an HIV integrase strand transfer inhibitor that prevents HIV from integrating its genetic material into host cell DNA.
GI265235 is an HIV integrase strand transfer inhibitor that prevents HIV from integrating its genetic material into host cell DNA. Used for HIV-1 infection in treatment-experienced adults.
At a glance
| Generic name | GI265235 |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | HIV integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The drug blocks integrase, an HIV enzyme essential for inserting viral DNA into the human genome. By inhibiting this step, it prevents HIV replication and reduces viral load in infected individuals. It is typically used as part of combination antiretroviral therapy.
Approved indications
- HIV-1 infection in treatment-experienced adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
Key clinical trials
- Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GI265235 CI brief — competitive landscape report
- GI265235 updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI